Liver transplantation for hepatocellular carcinoma

Expanding special priority to include stage III disease

Jeremy Goodman, Sean C. Glasgow, Mark Schnitzler, Jeffrey A. Lowell, Surendra Shenoy, Martin D. Jendrisak, Niraj M Desai, Mauricio Lisker-Melman, Jeffrey Crippin, William C. Chapman, Jean Nicholas Vauthey, John Brems, Scott Helton

Research output: Contribution to journalArticle

Abstract

Hypothesis: After liver transplantation, patients with stage III hepatocellular carcinoma (HCC) experience survivals similar to those of patients with less advanced disease and of matched control subjects. Design: Retrospective review of prospectively collected database. Setting: University hospital. Patients: Fifty-one adults with HCC and 153 matched adults without HCC who underwent orthotopic liver transplantation. Main Outcome Measures: One-, 3-, and 5-year survivals for all groups. After matching for year of transplantation, age, sex, and underlying liver disease, long-term survival was compared between groups. Rates of recurrence were also measured in the HCC groups. Results: From August 1, 1985, to February 28, 2002, we performed 635 adult liver transplantations, including 51 (8%) in patients with HCC. One hundred fifty-one patients without HCC who underwent transplantation were selected as controls. Patient demographic features were similar between case-control groups. The overall 5-year survival trend was worse for patients with HCC vs their matched controls (48% vs 65%; P=.07); however, this survival disadvantage was eliminated when patients with stages I through III HCC were combined and compared with their matched controls (59% vs 63%; P= .96). Survival of patients with stage III disease was comparable to that of matched controls (65% vs 59%; P=.44). Conclusions: For patients with stages I through III disease, long-term survival is comparable to that of matched controls, and only patients with stage IV disease experience poorer survival. Consideration should be given to granting exception points to patients with stage III disease.

Original languageEnglish (US)
Pages (from-to)459-464
Number of pages6
JournalArchives of Surgery
Volume140
Issue number5
DOIs
StatePublished - May 2005
Externally publishedYes

Fingerprint

Liver Transplantation
Hepatocellular Carcinoma
Survival
Transplantation
Liver Diseases
Demography
Outcome Assessment (Health Care)
Databases
Recurrence
Control Groups

ASJC Scopus subject areas

  • Surgery

Cite this

Goodman, J., Glasgow, S. C., Schnitzler, M., Lowell, J. A., Shenoy, S., Jendrisak, M. D., ... Helton, S. (2005). Liver transplantation for hepatocellular carcinoma: Expanding special priority to include stage III disease. Archives of Surgery, 140(5), 459-464. https://doi.org/10.1001/archsurg.140.5.459

Liver transplantation for hepatocellular carcinoma : Expanding special priority to include stage III disease. / Goodman, Jeremy; Glasgow, Sean C.; Schnitzler, Mark; Lowell, Jeffrey A.; Shenoy, Surendra; Jendrisak, Martin D.; Desai, Niraj M; Lisker-Melman, Mauricio; Crippin, Jeffrey; Chapman, William C.; Vauthey, Jean Nicholas; Brems, John; Helton, Scott.

In: Archives of Surgery, Vol. 140, No. 5, 05.2005, p. 459-464.

Research output: Contribution to journalArticle

Goodman, J, Glasgow, SC, Schnitzler, M, Lowell, JA, Shenoy, S, Jendrisak, MD, Desai, NM, Lisker-Melman, M, Crippin, J, Chapman, WC, Vauthey, JN, Brems, J & Helton, S 2005, 'Liver transplantation for hepatocellular carcinoma: Expanding special priority to include stage III disease', Archives of Surgery, vol. 140, no. 5, pp. 459-464. https://doi.org/10.1001/archsurg.140.5.459
Goodman, Jeremy ; Glasgow, Sean C. ; Schnitzler, Mark ; Lowell, Jeffrey A. ; Shenoy, Surendra ; Jendrisak, Martin D. ; Desai, Niraj M ; Lisker-Melman, Mauricio ; Crippin, Jeffrey ; Chapman, William C. ; Vauthey, Jean Nicholas ; Brems, John ; Helton, Scott. / Liver transplantation for hepatocellular carcinoma : Expanding special priority to include stage III disease. In: Archives of Surgery. 2005 ; Vol. 140, No. 5. pp. 459-464.
@article{22f40196e4354087b5c10926acc4a02f,
title = "Liver transplantation for hepatocellular carcinoma: Expanding special priority to include stage III disease",
abstract = "Hypothesis: After liver transplantation, patients with stage III hepatocellular carcinoma (HCC) experience survivals similar to those of patients with less advanced disease and of matched control subjects. Design: Retrospective review of prospectively collected database. Setting: University hospital. Patients: Fifty-one adults with HCC and 153 matched adults without HCC who underwent orthotopic liver transplantation. Main Outcome Measures: One-, 3-, and 5-year survivals for all groups. After matching for year of transplantation, age, sex, and underlying liver disease, long-term survival was compared between groups. Rates of recurrence were also measured in the HCC groups. Results: From August 1, 1985, to February 28, 2002, we performed 635 adult liver transplantations, including 51 (8{\%}) in patients with HCC. One hundred fifty-one patients without HCC who underwent transplantation were selected as controls. Patient demographic features were similar between case-control groups. The overall 5-year survival trend was worse for patients with HCC vs their matched controls (48{\%} vs 65{\%}; P=.07); however, this survival disadvantage was eliminated when patients with stages I through III HCC were combined and compared with their matched controls (59{\%} vs 63{\%}; P= .96). Survival of patients with stage III disease was comparable to that of matched controls (65{\%} vs 59{\%}; P=.44). Conclusions: For patients with stages I through III disease, long-term survival is comparable to that of matched controls, and only patients with stage IV disease experience poorer survival. Consideration should be given to granting exception points to patients with stage III disease.",
author = "Jeremy Goodman and Glasgow, {Sean C.} and Mark Schnitzler and Lowell, {Jeffrey A.} and Surendra Shenoy and Jendrisak, {Martin D.} and Desai, {Niraj M} and Mauricio Lisker-Melman and Jeffrey Crippin and Chapman, {William C.} and Vauthey, {Jean Nicholas} and John Brems and Scott Helton",
year = "2005",
month = "5",
doi = "10.1001/archsurg.140.5.459",
language = "English (US)",
volume = "140",
pages = "459--464",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Liver transplantation for hepatocellular carcinoma

T2 - Expanding special priority to include stage III disease

AU - Goodman, Jeremy

AU - Glasgow, Sean C.

AU - Schnitzler, Mark

AU - Lowell, Jeffrey A.

AU - Shenoy, Surendra

AU - Jendrisak, Martin D.

AU - Desai, Niraj M

AU - Lisker-Melman, Mauricio

AU - Crippin, Jeffrey

AU - Chapman, William C.

AU - Vauthey, Jean Nicholas

AU - Brems, John

AU - Helton, Scott

PY - 2005/5

Y1 - 2005/5

N2 - Hypothesis: After liver transplantation, patients with stage III hepatocellular carcinoma (HCC) experience survivals similar to those of patients with less advanced disease and of matched control subjects. Design: Retrospective review of prospectively collected database. Setting: University hospital. Patients: Fifty-one adults with HCC and 153 matched adults without HCC who underwent orthotopic liver transplantation. Main Outcome Measures: One-, 3-, and 5-year survivals for all groups. After matching for year of transplantation, age, sex, and underlying liver disease, long-term survival was compared between groups. Rates of recurrence were also measured in the HCC groups. Results: From August 1, 1985, to February 28, 2002, we performed 635 adult liver transplantations, including 51 (8%) in patients with HCC. One hundred fifty-one patients without HCC who underwent transplantation were selected as controls. Patient demographic features were similar between case-control groups. The overall 5-year survival trend was worse for patients with HCC vs their matched controls (48% vs 65%; P=.07); however, this survival disadvantage was eliminated when patients with stages I through III HCC were combined and compared with their matched controls (59% vs 63%; P= .96). Survival of patients with stage III disease was comparable to that of matched controls (65% vs 59%; P=.44). Conclusions: For patients with stages I through III disease, long-term survival is comparable to that of matched controls, and only patients with stage IV disease experience poorer survival. Consideration should be given to granting exception points to patients with stage III disease.

AB - Hypothesis: After liver transplantation, patients with stage III hepatocellular carcinoma (HCC) experience survivals similar to those of patients with less advanced disease and of matched control subjects. Design: Retrospective review of prospectively collected database. Setting: University hospital. Patients: Fifty-one adults with HCC and 153 matched adults without HCC who underwent orthotopic liver transplantation. Main Outcome Measures: One-, 3-, and 5-year survivals for all groups. After matching for year of transplantation, age, sex, and underlying liver disease, long-term survival was compared between groups. Rates of recurrence were also measured in the HCC groups. Results: From August 1, 1985, to February 28, 2002, we performed 635 adult liver transplantations, including 51 (8%) in patients with HCC. One hundred fifty-one patients without HCC who underwent transplantation were selected as controls. Patient demographic features were similar between case-control groups. The overall 5-year survival trend was worse for patients with HCC vs their matched controls (48% vs 65%; P=.07); however, this survival disadvantage was eliminated when patients with stages I through III HCC were combined and compared with their matched controls (59% vs 63%; P= .96). Survival of patients with stage III disease was comparable to that of matched controls (65% vs 59%; P=.44). Conclusions: For patients with stages I through III disease, long-term survival is comparable to that of matched controls, and only patients with stage IV disease experience poorer survival. Consideration should be given to granting exception points to patients with stage III disease.

UR - http://www.scopus.com/inward/record.url?scp=20944448139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20944448139&partnerID=8YFLogxK

U2 - 10.1001/archsurg.140.5.459

DO - 10.1001/archsurg.140.5.459

M3 - Article

VL - 140

SP - 459

EP - 464

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 5

ER -